SCHEMBL20079527

SCHEMBL20079527

Bc1nc(N)cc2cc(Br)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.46
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
PDPK1 O15530 2/20 0.40
JAK2 O60674 2/20 0.40
HTT P42858 1/20 0.37
PLAU P00749 1/20 0.37
PABPC1 P11940 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
ACHE P22303 3/20 0.36
CYP2A6 P11509 1/20 0.35
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
MMP13 P45452 1/20 0.33
NOS1 P29475 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30005359 0.82 BACE1 (0.47) BACE1MEN1MAPTKMT2AKDM4E
SCHEMBL1520112 0.82 BACE1 (0.47) BACE1MEN1MAPTKMT2AKDM4E
SCHEMBL23048737 0.78 BACE1 (0.44) BACE1MEN1MAPTKMT2AKDM4E
SCHEMBL19546876 0.78 BACE1 (0.44) BACE1MEN1MAPTKMT2AKDM4E
SCHEMBL8176768 0.72 NCF1 (0.50) BACE1MEN1MAPTKMT2AKDM4E
SCHEMBL9921934 0.71 BACE1 (0.32) BACE1MAPTKDM4E
SCHEMBL24808798 0.70 KDM4E (0.48) BACE1MEN1MAPTKMT2AKDM4E
SCHEMBL393406 0.67 HTT (0.43) BACE1MEN1MAPTKMT2AKDM4E
SCHEMBL11346168 0.65 BACE1 (0.53) BACE1MAPTPDPK1JAK2HTT
SCHEMBL17646468 0.65 BACE1 (0.59) BACE1ACHENOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286945-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF TENARX, INC. 2023-09-14 US disclosed
US-11673881-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-13 US disclosed
US-11548872-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-01-10 US disclosed
EP-3892276-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS BioSplice Therapeutics, Inc. (US) 2021-10-13 EP disclosed
US-9951048-B1 Isoquinolin-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2018-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673881-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof DYRK1A, DYRK3, DYRK1B BACE1 1111/4885MEN1 4483/4885MAPT 577/4885
US-20230286945-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF WNT1, WNT3, WNT3A BACE1 1926/4885MEN1 4429/4885MAPT 2111/4885
US-11548872-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof WNT1, WNT3, WNT3A BACE1 1926/4885MEN1 4429/4885MAPT 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.